Table 2.
Overall baseline characteristics of the KNW participants and categorized for module use (N=231).
|
|
Overall (N=231) | No module (n=33, 14.3%) |
KNW Modules | ||||||||
| Fatigue (n=82, 35.5%) |
Return to work (n=53, 22.9%) |
Mood (n=49, 21.2%) |
Relation-ships (n=38, 16.5%) |
Physical activity (n=51, 22.1%) |
Diet (n=134, 58%) |
Smoking (n=23, 10%) |
Residual symptoms (n=47, 20.4%) |
||||
| Female, n (%) | 183 (79.2) |
26 (78.8) |
63 (76.8) |
46 (86.8) |
41 (83.7) |
30 (79.0) |
44 (86.3) |
106 (79.1) |
17 (73.9) |
40 (85.1) |
|
| Age, mean (SD) | 55.6 (11.5) |
52.5 (10.7) |
55.1 (11.6) |
52.8 (9.5) |
54.4 (11.7) |
55.9 (12.1) |
56.3 (9.7) |
56.0 (11.1) |
51.6 (8.7) |
56.2 (9.0) |
|
| With partner, n (%) | 193 (83.6) |
27 (81.8) |
65 (79.3) |
43 (81.1) |
37 (75.5) |
31 (81.6) |
42 (82.4) |
109 (81.3) |
16 (69.6) |
36 (76.6) |
|
| BMI, mean (SD) | 26.0 (5.0) |
27.2 (7.3) |
26.2 (4.3) |
25.7 (5.0) |
25.3 (4.0) |
26.1 (3.5) |
26.1 (3.6) |
25.4 (4.7) |
24.8 (3.1) |
25.4 (3.9) |
|
| Education, n (%) | |||||||||||
|
|
Low | 76 (32.9) |
13 (39.4) |
23 (28.1) |
12 (22.6) |
15 (30.6) |
12 (31.6) |
18 (35.3) |
42 (31.3) |
9 (39.1) |
13 (27.7) |
|
|
Medium | 76 (32.9) |
12 (36.4) |
31 (37.8) |
20 (37.7) |
20 (40.8) |
13 (34.2) |
18 (35.3) |
44 (32.8) |
7 (30.4) |
14 (29.8) |
|
|
High | 79 (34.2) |
8 (24.2) |
28 (34.2) |
21 (39.6) |
14 (28.6) |
13 (34.2) |
15 (29.4) |
48 (35.8) |
7 (30.4) |
20 (42.6) |
| Working at baseline, n (%) | 122 (52.8) |
20 (60.6) |
40 (48.8) |
38 (71.7) |
28 (57.1) |
18 (47.4) |
27 (52.9) |
70 (52.2) |
13 (56.5) |
26 (55.3) |
|
| Type of cancer, n (%) | |||||||||||
|
|
Breast | 162 (70.1) |
24 (72.7) |
55 (67.1) |
40 (75.5) |
36 (73.5) |
27 (71.1) |
41 (80.4) |
94 (70.2) |
18 (78.3) |
32 (68.1) |
|
|
Colon | 29 (12.6) |
4 (12.1) |
10 (12.2) |
4 (7.6) |
6 (12.2) |
5 (13.2) |
2 (3.9) |
19 (14.2) |
3 (13.0) |
9 (19.2) |
|
|
Other | 40 (17.3) |
5 (15.2) |
17 (20.7) |
9 (16.9) |
7 (14.3) |
6 (15.8) |
8 (15.7) |
21 (15.7) |
2 (8.7) |
6 (12.8) |
| Had cancer before, n (%) | 24 (10.4) |
5 (15.2) |
8 (9.8) |
3 (5.7) |
4 (8.2) |
3 (7.9) |
5 (9.8) |
13 (9.7) |
2 (8.7) |
5 (10.6) |
|
| Treatment, n (%) | |||||||||||
|
|
Surgery, chemo, radio | 86 (37.2) |
11 (33.3) |
37 (45.1) |
20 (37.7) |
20 (40.8) |
18 (47.4) |
22 (43.1) |
53 (39.6) |
11 (47.8) |
22 (46.8) |
|
|
Surgery, chemo | 61 (26.4) |
11 (33.3) |
17 (20.7) |
16 (30.2) |
16 (32.7) |
9 (23.7) |
12 (23.5) |
35 (26.1) |
7 (30.4) |
15 (31.9) |
|
|
Surgery, radio | 46 (19.9) |
5 (15.2) |
15 (18.3) |
11 (20.8) |
10 (20.4) |
5 (13.2) |
11 (21.6) |
26 (19.4) |
3 (13.0) |
8 (17.1) |
|
|
Other | 38 (16.5) |
6 (18.2) |
13 (15.9) |
6 (11.3) |
3 (6.1) |
6 (15.8) |
6 (11.8) |
20 (14.9) |
2 (8.7) |
2 (4.3) |
|
|
Weeks since completion treatment, mean (SD) | 25.1 (13.5) |
27.1 (15.6) |
24.1 (14.4) |
22.3 (13.7) |
25.3 (13.6) |
26.5 (12.9) |
23.7 (13.6) |
25.0 (13.1) |
22.1 (13.2) |
25.4 (3.9) |
| Having comorbidities, n (%) | 62 (26.8) |
10 (30.3) |
25 (30.5) |
14 (26.4) |
12 (24.5) |
10 (26.3) |
15 (29.4) |
34 (25.4) |
7 (30.4) |
8 (17.0) |
|
| Using aftercare, n (%) | 145 (62.8) |
25 (75.8) |
46 (56.1) |
38 (71.7) |
32 (65.3) |
29 (76.3) |
31 (60.8) |
83 (61.9) |
12 (52.2) |
29 (61.7) |
|